Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,012.82 USD

1,012.82
1,071,783

-1.77 (-0.17%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $1,012.36 -0.46 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q2

by Zacks Equity Research

Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2022.

Company News for Aug 4, 2022

by Zacks Equity Research

Companies in The News Are: MRNA, REGN, HZNP, EXC

Regeneron (REGN) Q2 Earnings & Sales Beat on Eylea, Dupixent

by Zacks Equity Research

Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.

U.S. Stock Futures Rise on Strong Q2 Earnings

by Zacks Equity Research

Stock futures have risen in today¿¿¿s pre-market after two consecutive days of loss making.

Pre-markets Green on Strong Earnings Numbers

by Zacks Equity Research

Pre-markets Green on Strong Earnings Numbers.

Regeneron (REGN) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Regeneron (REGN) delivered earnings and revenue surprises of 14.54% and 3.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q2

by Zacks Equity Research

Alnylam's (ALNY) earnings and sales fall shy of estimates in the second quarter of 2022. The company maintains its revenue guidance for 2022.

What is in Store for Regeneron (REGN) This Earnings Season?

by Zacks Equity Research

Regeneron's (REGN) second-quarter earnings might have gotten a boost from the solid performance of Eylea and Dupixent.

Sanofi (SNY) Q2 Earnings & Sales Beat, Ups 2022 Growth View

by Zacks Equity Research

Sanofi (SNY) beats second-quarter estimates for earnings and sales. Dupixent drives sales growth and a strong recovery in travel vaccines. The company raises its earnings growth guidance for 2022.

Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed the most recent trading day at $587.28, moving +0.2% from the previous trading session.

Roche (RHHBY) 1H22 Earnings, Sales Grow, View Disappoints

by Zacks Equity Research

Roche (RHHBY) performance in the first half was decent on demand for its diagnostics base business and new drugs. Demand for COVID-19 tests is likely to fall in the second half.

Regeneron (REGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed at $595.73 in the latest trading session, marking a +1.54% move from the prior day.

Roche (RHHBY) Announces 2-Year Data on Vabysmo for nAMD

by Zacks Equity Research

Roche's (RHHBY) new two-year data reinforce the long-term efficacy, safety and durability of Vabysmo in wet age-related mtacular degeneration.

Kinjel Shah headshot

Pharma Stock Roundup: MRK Buys Cancer Drug Rights, SNY Dupixent Kids Study Succeeds

by Kinjel Shah

Merck (MRK) buys co-development rights to prostate cancer candidate. FDA grants full approval to Pfizer's (PFE) COVID-19 vaccine for adolescents.

Sanofi (SNY) Dupixent Esophagitis Kids Study Meets Goal

by Zacks Equity Research

Sanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase III pivotal study in children 1 to 11 years of age.

The Zacks Analyst Blog Highlights Coca-Cola, Merck, Toyota Motor, Enbridge, and Regeneron Pharmaceuticals

by Zacks Equity Research

Coca-Cola, Merck, Toyota Motor, Enbridge, and Regeneron Pharmaceuticals are part of Zacks top Analyst Blog.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Regeneron (REGN) Stock Moves -0.71%: What You Should Know

by Zacks Equity Research

In the latest trading session, Regeneron (REGN) closed at $610.09, marking a -0.71% move from the previous day.

Mark Vickery headshot

Top Stock Reports for Coca-Cola, Merck & Toyota Motor

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Company (KO), Merck & Co., Inc. (MRK) and Toyota Motor Corp. (TM).

Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed at $594.90 in the latest trading session, marking a -0.28% move from the prior day.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB